Ali J. Satvat - 30 Dec 2024 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
30 Dec 2024
Net transactions value
+$2,585,134
Form type
4
Filing time
31 Dec 2024, 17:52:25 UTC
Previous filing
25 Jun 2024
Next filing
13 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise $875,925 +79,702 $10.99 79,702 30 Dec 2024 Direct
transaction BBIO Common Stock Options Exercise $664,715 +39,851 +50% $16.68 119,553 30 Dec 2024 Direct
transaction BBIO Common Stock Options Exercise $1,044,495 +39,851 +33% $26.21 159,404 30 Dec 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (Right to Buy) Options Exercise $0 -79,702 -100% $0.000000 0 30 Dec 2024 Common Stock 79,702 $10.99 Direct F1
transaction BBIO Stock Option (Right to Buy) Options Exercise $0 -39,851 -100% $0.000000 0 30 Dec 2024 Common Stock 39,851 $16.68 Direct F1
transaction BBIO Stock Option (Right to Buy) Options Exercise $0 -39,851 -100% $0.000000 0 30 Dec 2024 Common Stock 39,851 $26.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option was fully vested and exercisable on the date of issuance by the Issuer as of January 26, 2021.